Clinical Trial: A prospective phase II clinical study of Trastuzumab Rezetecan for Injection combined with Iparomlimab and Tuvonralimab Injection versus TAC regimen as neoadjuvant therapy for early or locally advanced HR-positive/HER2-low breast cancer (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective phase II clinical study of Trastuzumab Rezetecan for Injection combined with Iparomlimab and Tuvonralimab Injection versus TAC regimen as neoadjuvant therapy for early or locally advanced HR-positive/HER2-low breast cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130563

Registration Time: 2026/08/21

Type: Interventional study

Primary Sponsor: Cancer Hospital of Shandong First Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337476

Published by HT Digital Content Services with permission from Health Daily Digest....